Can aspirin stop liver cancer in Hepatitis B patients? - Erie News Now | WICU & WSEE in Erie, PA

Can aspirin stop liver cancer in Hepatitis B patients?

Updated:
© DigitalVision / Thinkstock © DigitalVision / Thinkstock
  • Chris Lifestyle Category TESTMore>>

  • COPY-Chris Test 2

    Chris Test 2

    Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1More >>
  • Chris Test 1

    Chris Test 1

    Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1More >>

(HealthDay News) -- Daily aspirin may reduce the risk of liver cancer for people with hepatitis B infection, a new study suggests.

Hepatitis B virus attacks the liver and can cause cirrhosis and liver cancer. Previous research suggests daily low-dose aspirin therapy may prevent cancer, but there is little clinical evidence on whether regular aspirin use can prevent liver cancer in people with hepatitis B.

Researchers from Taiwan analyzed data from close to 205,000 patients with chronic hepatitis B. They found that those on daily aspirin were much less likely to develop liver cancer over five years than those who did not take aspirin.

It's important to note, however, that the study only found these associations, but did not establish a cause-and-effect link.

The findings are scheduled to be presented Monday at an American Association for the Study of Liver Diseases meeting, in Washington, D.C.

About 240 million people worldwide have chronic hepatitis B, according to the association.

While antiviral medicines can significantly reduce liver cancer risk in people with the hepatitis B virus (HBV), they don't eliminate it and are not appropriate for everyone, said lead investigator Dr. Teng-Yu Lee.

Lee is a researcher in the department of gastroenterology at Taichung Veterans General Hospital.

"For effectively preventing HBV-related liver cancer, the findings of this study may help hepatologists treat patients with chronic HBV infection in the future, particularly for those who are not indicated for antiviral therapy. We are pursuing prospective investigations for further confirming the findings," Lee said in a meeting news release.

Research presented at medical meetings is typically considered preliminary until published in a peer-reviewed journal.

More information

The U.S. Centers for Disease Control and Prevention has more on hepatitis B.

Copyright © 2017 HealthDay. All rights reserved.

*DISCLAIMER*: The information contained in or provided through this site section is intended for general consumer understanding and education only and is not intended to be and is not a substitute for professional advice. Use of this site section and any information contained on or provided through this site section is at your own risk and any information contained on or provided through this site section is provided on an "as is" basis without any representations or warranties.
Powered by Frankly
3514 State St. Erie, PA 16508
Newsroom: (814) 454-8812
Business offices: (814) 454-5201
WICU FCC Filing
WSEE FCC Filing
Share:
Share Stories
Submit your stories to our site!
Share Photos
Share your photos in our community galleries
RSS Feeds
All content © Copyright 2000 - 2018 WICU. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.
                   WICU/WSEE - 3514 State Street Erie, PA 16508 - (814) 454-5201 - info@wicu12.com